Efficacy and Safety of Biosimilar Cetuximab (CETUXA) in Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck: A Retrospective Multicenter Analysis. JOC [Internet]. 2025 Dec. 1 [cited 2025 Dec. 26];24(10s):382-9. Available from: https://carcinogenesis.com/index.php/JOC/article/view/1662